REGENXBIO's stock plummeted by 22% after the FDA placed a clinical hold on its RGX-121 gene therapy trial. The halt was due to a surprise finding, causing investor concern.

An analysis discusses potential future FDA reversals in drug approvals, referencing recent cases involving UniQure and Regenxbio.

Investors are advised to check Regenxbio Inc (RGNX) stock's cash runway before making a purchase decision.

Regenxbio secured a legal victory against Sarepta in an appeals court regarding a patent dispute.

REGENXBIO has announced a regulatory update concerning its investigational gene therapy, RGX-121, for the treatment of Mucopolysaccharidosis Type II (MPS II).

AbbVie's deal with Apogee and Regenxbio's progress on a gene therapy drug are highlighted as key factors influencing stock movements.

Regenxbio has outlined a potential accelerated approval pathway for its gene therapy RGX-202 in 2027, following positive results from its pivotal Phase III primary endpoint.

MediWound reported a GAAP EPS of -$0.56, which beat estimates by $0.07, but its revenue of $1.87 million missed expectations by $0.22 million.

REGENXBIO's stock experienced a dip in value following the announcement of a $100 million equity offering. This financial move often impacts investor sentiment and stock performance.

Regenxbio and Replimune were among the top gainers in the biotech sector following a U-turn by the FDA regarding UniQure, indicating a positive market response to the regulatory development.

Regenxbio's shares have increased after the company announced positive results from its Duchenne trial.

An earnings preview for Regenxbio's fourth quarter 2025 financial results has been published.